Arlene O. Siefker-Radtke, MD, discusses the use of erdafitinib in urothelial carcinoma.
Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of erdafitinib (Balversa) in urothelial carcinoma.
Erdafitinib, a novel targeted therapy that targets FGFR3-altered urothelial carcinoma, is a promising agent for patients with FGFR-driven disease, Siefker-Radtke says. In a phase 2 trial (NCT02365597), the drug demonstrated an overall response rate of 40% in patients with metastatic disease who had received prior chemotherapy, Siefker-Radtke explains.
As immunologically cold tumors appear to enrich FGFR3 alterations, determining optimal sequencing in patients with FGFR3-altered urothelial carcinoma is important, Siefker-Radtke notes. The phase 3 THOR trial (NCT03390504) is currently ongoing to determine whether these patients should receive erdafitinib or immune checkpoint inhibition first, Siefker-Radtke says. This trial is studying erdafitinib vs pembrolizumab (Keytruda) in patients with FGFR-altered advanced urothelial carcinoma who have received prior therapy, Siefker-Radtke concludes.